AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
FDA gives approval for phase III registrational trial for breast cancer drug.
2003 DEC 4 - (NewsRx.com & NewsRx.net) -- YM BioSciences Inc. (YMBA) has received written confirmation from the U.S. Food and Drug Administration (FDA) that it may initiate a pivotal phase III, or registrational trial, for its lead small-molecule anti-cancer therapeutic, tesmilifene.
"We are extremely pleased the FDA has cleared us to begin this trial and look forward to establishing tesmilifene's ability to enhance traditional chemotherapies and extend the survival time of women with metastatic breast cancer, as the drug has demonstrated in a previous phase III trial," said David Allan, chairman and chief executive officer of YM BioSciences.
"The incorporation of a sequential design into the protocol creates the possibility of significantly reduced trial time and costs compared with the usual, classic phase III trial design in this indication."
The planned multi-center international trial will compare the overall survival times of advanced metastatic/recurrent breast cancer patients receiving tesmilifene in combination with epirubicin (an anthracycline) and cyclophosphamide versus epirubicin/cyclophosphamide alone. The primary endpoint of this pivotal trial is survival.
The FDA has approved the incorporation of a sequential design into the trial protocol, enabling an interim analysis to be made by an independent Data Monitoring Board after 50% of the planned number of events (deaths) have occurred, and if necessary every 6 months thereafter, without incurring any statistical penalty.
If the required survival differential is ...
- CAELYX Demonstrates Efficacy and Reduced Cardiac Toxicity in First-Line...
- Press release article from: PR Newswire March 11, 2004 700+ words
...of a randomised Phase III clinical study demonstrated...treatment of metastatic breast cancer with significantly...visceral disease. Phase III Study Results In the Phase III clinical study...with metastatic breast cancer were randomised...
- Genentech's Avastin Phase III Misses Breast Cancer Endpoint.
- Magazine article from: BIOWORLD Today November 4, 2009 700+ words
...regarding Avastin data from a Phase III study in breast cancer broke Tuesday, and...been completed. In the Phase III breast cancer study, patients were...percent to 20 percent on the breast cancer Phase III news, although the damage...
- GENENTECH'S AVASTIN PHASE III MISSES BREAST CANCER ENDPOINT.(Brief Article)
- Magazine article from: BIOWORLD Today Osborne, Randall September 11, 2002 700+ words
...regarding Avastin data from a Phase III study in breast cancer broke Tuesday, and...been completed. In the Phase III breast cancer study, patients were...percent to 20 percent on the breast cancer Phase III news, although the damage...
- Biomira Phase Ii Colorectal Trial Results For Theratope(R) Vaccine Presented At...
- Press release article from: PR Newswire June 2, 2003 700+ words
...chemotherapy. As well, a Phase III demographic study of...patients with metastatic breast cancer found that treatment...ulcerations in four patients. Phase III Demography Data for Metastatic Breast Cancer The Phase III demography data represent...
- First Patient Enrolled in Global Phase III Study of Bevacizumab and Trastuzumab...
- Press release article from: PR Newswire May 27, 2008 700+ words
...Therapy in HER2-positive Breast Cancer) study is a Phase III clinical research trial...late HER2-positive breast cancer. This is the first Phase III trial to evaluate combining...treating early stage breast cancer. ABOUT THE CANCER INTERNATIONAL...
- Phase III Trial With Avastin in Relapsed Metastatic Breast Cancer Does Not Meet...
- Press release article from: Business Wire September 9, 2002 700+ words
...announced that a Phase III study of Avastin...relapsed metastatic breast cancer patients did...with Avastin in breast cancer, we are disappointed in the Phase III efficacy results...line metastatic breast cancer trial, and a Phase III ...
- RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic...
- Press release article from: PR Newswire December 12, 2008 700+ words
...positive metastatic breast cancer. These results...initiation of a Phase III clinical trial...Afinitor(R)) in breast cancer. Two Phase I...treatment regimen in breast cancer, as well as studying...initiate a worldwide Phase III clinical trial...
- Preliminary Results From Phase III Study Demonstrate Herceptin / Chemotherapy...
- Press release article from: Business Wire December 11, 2002 700+ words
...positive metastatic breast cancer patients. The randomized Phase III trial demonstrated...HER2-positive breast cancer have an aggressive...The pivotal Phase III Herceptin trial...positive metastatic breast cancer, and randomized...